- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Telix Pharmaceuticals Ltd (TLX)
Sydney
Symbol | Exchange | Currency |
|---|
4.760
+0.030(+0.63%)
- Volume:841,699
- Bid/Ask:4.760/4.770
- Day's Range:4.630 - 4.800
TLX Overview
- Prev. Close
- 4.73
- Day's Range
- 4.63-4.8
- Revenue
- 30.19M
- Open
- 4.71
- 52 wk Range
- 3.55-8.82
- EPS
- -0.403
- Volume
- 841,699
- Market Cap
- 1.49B
- Dividend (Yield)
- N/A(N/A)
- Average Volume (3m)
- 1,469,268
- P/E Ratio
- -14.97
- Beta
- 2.36
- 1-Year Change
- -19.38%
- Shares Outstanding
- 313,037,968
- Next Earnings Date
- 29 Nov 2022
What is your sentiment on Telix Pharma?
or
Market is currently closed. Voting is open during market hours.
Telix Pharmaceuticals Ltd News
- Australian Shares Tick 0.1% Higher, Telix Surges 12.6% After Reporting
- ByInvesting.com-
By Oliver Gray Investing.com - The S&P/ASX 200 added 6.80 points or 0.10% to 6,766.00 after the first hour of Thursday’s trade, easing slightly from a 1.7% rally in the previous...
- BRIEF-Telix Pharmaceuticals Establishes Asia Pacific Operating Region
- ByReuters-
May 3 (Reuters) - Telix Pharmaceuticals Ltd TLX.AX : * ESTABLISHMENT OF ASIA PACIFIC OPERATING REGION * DAVID CADE APPOINTED PRESIDENT OF TELIX APAC
Telix Pharmaceuticals Ltd Analysis
- Oil’s Iran Cliffhanger: What To Know And What To Expect
EU attempting to revive Iran nuclear deal with market staying pessimistic Crude prices could rebound from oversold conditions but stay off 2022 highs Both Iran, US likely looking...
Telix Pharmaceuticals Ltd Company Profile
Telix Pharmaceuticals Ltd Company Profile
Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation (MTR) products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company focuses on developing diagnostic and therapeutic products using MTR. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase I/II clinical trials and TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); and TLX66, which is in Phase I/IIa clinical trials for the treatment of bone marrow conditioning and rare diseases. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; TLX591-Sx, a positron emission tomography (PET) tracer that delivers PET and fluorescent (optical) imaging; and TLX599-CDx, an investigational prostate cancer imaging agent that uses single photon emission computed tomography. It has a strategic license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for developing a portfolio of MTR products; scientific and clinical research collaboration with Mauna Kea Technologies; and strategic collaboration agreement with Lightpoint Medical, Ltd. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
Read More
Analyst Price Target
| Average | 9.242 (+94.16% Upside) |
| High | 13.5 |
| Low | 6.8 |
| Price | 4.76 |
| No. of Analysts | 6 |
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Analysts 12-Month Price Target
Technical Summary
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Buy | Sell | Strong Sell | Neutral |
| Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Strong Sell | Strong Sell |
| Summary | Strong Buy | Strong Buy | Neutral | Strong Sell | Sell |
Trending Stocks
Trending Stocks
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 7.17 | 7.30 | 7.135 | +0.080 | +1.13% | 7.76M | Sydney | |||
| 4.98 | 5.06 | 4.87 | -0.04 | -0.80% | 4.75M | Sydney | |||
| 1.35 | 1.355 | 1.345 | 0.00 | 0.00% | 0.00 | Sydney | |||
| 33.50 | 34.16 | 33.50 | -0.450 | -1.33% | 1.11M | Sydney | |||
| 3.56 | 3.66 | 3.53 | -0.070 | -1.93% | 22.14M | Sydney | |||
| 151.41 | 153.40 | 149.51 | -1.330 | -0.87% | 906.59K | Sydney | |||
| 11.81 | 11.87 | 11.66 | -0.04 | -0.34% | 217.88K | Sydney | |||
| 0.021 | 0.021 | 0.021 | 0.00 | 0.00% | 0.00 | Sydney | |||
| 4.01 | 4.07 | 3.99 | -0.030 | -0.74% | 1.82M | Sydney | |||
| 32.05 | 32.49 | 31.66 | +0.390 | +1.23% | 3.77M | Sydney | |||
| 1.01 | 1.015 | 1.01 | 0.00 | 0.00% | 0.00 | Sydney | |||
| 90.61 | 91.37 | 89.66 | -0.090 | -0.10% | 2.01M | Sydney | |||
| 22.77 | 23.03 | 22.60 | -0.030 | -0.13% | 3.71M | Sydney | |||
| 3.06 | 3.11 | 2.96 | -0.06 | -1.92% | 556.99K | Sydney | |||
| 26.73 | 28.00 | 26.70 | -1.04 | -3.75% | 177.13K | Sydney |